Daily treatment with Zilbrysq (zilucoplan) was safe and effective in people with generalized myasthenia gravis (gMG) who were switching from Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz), according to results from a small U.S. clinical trial. All of these medications belong to a class of therapies…
News
Azathioprine did not outperform standard treatment in helping adults with myasthenia gravis (MG) live longer, and while older age alone increased the risk of death, using azathioprine for many years was linked to serious blood problems and cases of cancer, a study has found. However, “although the use of…
Povetacicept, a treatment for autoimmune diseases in the pipeline of Vertex Pharmaceuticals, reduced disease activity in a study with a mouse model of myasthenia gravis (MG) by lowering the levels of disease-causing antibodies in the bloodstream. Researchers also observed that povetacicept outperformed efgartigimod — approved as Vyvgart…
Treatment with Vyvgart (efgartigimod) eased hard-to-treat symptoms for a trio of women with generalized myasthenia gravis (gMG) who tested negative for three antibodies commonly seen in the disease, according to a case series from China. Per the researchers, “this report describes three patients with triple-[seronegative] gMG successfully treated with efgartigimod,”…
Vor Bio has signed an exclusive license agreement to develop and market Remegen’s telitacicept — a B-cell-targeting candidate for the treatment of myasthenia gravis (MG) and other autoimmune diseases driven by self-reactive antibodies — outside of China, Hong Kong, Macau, and Taiwan. Telitacicept has been approved…
Telitacicept, a B-cell-targeting therapy for myasthenia gravis (MG), has been granted orphan drug status in the European Union, according to its developer Remegen. Orphan drug designation, or ODD, is awarded to medications that treat conditions affecting fewer than 5 in 10,000 people in the EU. The designation’s…
A six-week program that combines inspiratory muscle training (IMT) and aerobic exercise may improve respiratory function in adults with myasthenia gravis (MG), a study in Taiwan shows. Those who followed the training showed strengthened respiratory muscles, improved lung function, reduced breathlessness, and enhanced physical fitness over those who received…
Women who have surgery to remove their thymus gland to treat myasthenia gravis (MG) tend to have experienced symptoms earlier in life than men, but waited longer to receive a diagnosis, a study reports. However, after the surgery, called a thymectomy, female patients have higher rates of complete…
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 2 clinical trial testing IM-101, ImmunAbs’ investigational therapy for myasthenia gravis (MG). The multicenter, placebo-controlled trial is expected to enroll up to 90 people with MG who will receive IM-101 or a placebo once monthly.
The first patient has joined a Phase 3 clinical trial assessing the safety and efficacy of Descartes-08, an investigational cell therapy for myasthenia gravis (MG) being developed by Cartesian Therapeutics. Called AURORA (NCT06799247), the trial is expected to enroll 100 adults with generalized MG (gMG), a more…
Recent Posts
- Doctors say MG doesn’t cause pain, but my body suggests otherwise
- Taking Vyvgart before thymectomy may help improve surgery outcomes
- Finding ways to reduce suffering, even while living with chronic pain
- Guest Voice: What living between labels taught me about MG
- MG-specific treatments needed for older patients, researchers say